MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Banoxantrone dihydrochloride

CAS No. : 252979-56-9

MCE 站：Banoxantrone dihydrochloride

产品活性：Banoxantrone dihydrochloride 是一种新型生物还原剂，可还原成稳定的 DNA 亲和性化合物 AQ4，AQ4 是一种有效的拓扑异构酶II抑制剂。

研究领域：Cell Cycle/DNA Damage

作用靶点：Topoisomerase

In Vitro: Banoxantrone (AQ4N) can be reduced in a hypoxic environment to a stable DNA-affinic agent AQ4. AQ4, a potent topoisomerase II inhibitor, would be capable of damaging cells recruited into the cell cycle following radiation damage to the well-oxygenated cells of the tumor. Banoxantrone shows more than 8-fold higher cytotoxicity under hypoxia than normoxia in cultures of 9L rat gliosarcoma and H460 human non-small-cell lung carcinoma cells but not for 11 other human cancer cell lines. DT-diaphorase protein levels and banoxantrone chemosensitivity are poorly correlated across the cancer cell line panel, and banoxantrone chemosensitivity is not affected by DT-diaphorase inhibitors. Banoxantrone is a bis-N-oxide that is reduced via two sequential two-electron reductions to the tertiary amine, AQ4, which is a potent cytotoxic agent toward both aerobic and hypoxic cells. AQ4, but not AQ4N, intercalates in DNA with high affinity to generate a stable persistent complex that can inhibit topoisomerase II and cause DNA damage and cell death.

In Vivo: Banoxantrone (200 mg/kg) significantly enhances the tumor growth delay caused by radiation. This occurred when radiation is administered both as a single dose (12 Gy) and in a multifraction regimen (5x3 Gy). A study of the scheduling of Banoxantrone (AQ4N) administration shows that there is a very long time period over which a maximal effect can be elicited (drug given 4 days before to 6 h after radiation). These results suggest that Banoxantrone has significant potential as a bioreductive drug. The activation of banoxantrone cytotoxicity in vivo requires tumor hypoxia that is more extensive or prolonged than can readily be achieved by vasodilation or by antiangiogenic drug treatment. Incorporation of banoxantrone into conventional chemoradiation protocols therefore targets both oxygenated and hypoxic regions of tumors, and potentially will increase the effectiveness of therapy. A single dose of 60 mg/kg banoxantrone enhances the response of RT112 (bladder) and Calu-6 (lung) xenografts to treatment with cisplatin and radiation therapy. Banoxantrone will increase the efficacy of chemoradiotherapy in preclinical models.

相关产品：Natural Product Like Compound Library  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Anti-Blood Cancer Compound Library  |  Doxorubicin hydrochloride  |  Etoposide  |  Irinotecan  |  SN-38  |  Camptothecin  |  Topotecan Hydrochloride  |  Epirubicin hydrochloride  |  Daunorubicin hydrochloride  |  Exatecan mesylate  |  Suramin sodium salt  |  Berberine chloride  |  Mitoxantrone  |  Betulinic acid  |  EIDD-1931  |  Idarubicin hydrochloride  |  Aldoxorubicin  |  β-Lapachone  |  Teniposide  |  Hycanthone  |  Pirarubicin  |  Bisantrene  |  Aclacinomycin A hydrochloride  |  Amsacrine  |  Daun02

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。